Gossamer Bio, Inc. (GOSS)
8.86
-0.03
(-0.34%)
USD |
NASDAQ |
Oct 16, 13:29
Gossamer Bio SG&A Expense (TTM) : 47.94M for June 30, 2026
SG&A Expense (TTM) Chart
Historical SG&A Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 47.94M |
| March 31, 2026 | 47.72M |
| December 31, 2025 | 37.63M |
| September 30, 2025 | 36.12M |
| June 30, 2025 | 35.23M |
| March 31, 2025 | 35.22M |
| December 31, 2024 | 36.13M |
| September 30, 2024 | 35.80M |
| June 30, 2024 | 36.58M |
| March 31, 2024 | 37.89M |
| December 31, 2023 | 38.46M |
| September 30, 2023 | 42.23M |
| June 30, 2023 | 44.44M |
| March 31, 2023 | 45.74M |
| December 31, 2022 | 47.61M |
| September 30, 2022 | 45.49M |
| June 30, 2022 | 46.45M |
| March 31, 2022 | 46.44M |
| Date | Value |
|---|---|
| December 31, 2021 | 45.78M |
| September 30, 2021 | 50.94M |
| June 30, 2021 | 49.93M |
| March 31, 2021 | 50.33M |
| December 31, 2020 | 49.73M |
| September 30, 2020 | 45.44M |
| June 30, 2020 | 43.83M |
| March 31, 2020 | 41.85M |
| December 31, 2019 | 39.14M |
| September 30, 2019 | 41.48M |
| June 30, 2019 | 54.55M |
| March 31, 2019 | 49.48M |
| December 31, 2018 | 44.05M |
| September 30, 2018 | 30.27M |
| June 30, 2018 | 7.443M |
| March 31, 2018 | 2.837M |
| December 31, 2017 | 0.233M |
| September 30, 2017 | 0.076M |
SG&A Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (TTM) Benchmarks
| United Therapeutics Corp. | 644.60M |
| Arbutus Biopharma Corp. | 16.49M |
| Kura Oncology, Inc. | 135.28M |
| ACADIA Pharmaceuticals, Inc. | 620.29M |
| Alnylam Pharmaceuticals, Inc. | 1.318B |